TTNPB
Based on 6 publication(s) in Google Scholar
TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC50s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 71441-28-6
- Formula: C24H28O2
- Molecular Weight:348.48
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Nuclear Receptor Compound Library
HY-L126
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Vitamin Compound Library
HY-L197
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) TTNPB
More
Customer Validation & Images
-
Flow Cytometry
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
IC50: 5.1 nM (RARα), 4.5 nM (RARβ), 9.3 nM (RARγ)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CV-1 | EC50 |
>10000 nM
Compound: TTNPB
|
Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells
|
[PMID: 8308867] |
| CV-1 | EC50 |
>10000 nM
Compound: TTNPB
|
Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells
|
[PMID: 8308867] |
| CV-1 | EC50 |
2 nM
Compound: TTNPB
|
Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells
|
[PMID: 8308867] |
| CV-1 | EC50 |
3 nM
Compound: TTNPB
|
Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells
|
[PMID: 8308867] |
| CV-1 | EC50 |
30 nM
Compound: TTNPB
|
Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells
|
[PMID: 8308867] |
| CV-1 | EC50 |
>10000 nM
Compound: TTNPB
|
Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells
|
[PMID: 8308867] |
| F9 | ED50 |
0.08 nM
Compound: 2
|
Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay
Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay
|
[PMID: 2738885] |
| F9 | ED50 |
1.5 nM
Compound: 2
|
Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay
Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay
|
[PMID: 2738885] |
| HEK293 | EC50 |
0.18 nM
Compound: TTNPB
|
Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 25305688] |
| HL-60 | IC50 |
46 μM
Compound: 3
|
In vitro cytotoxicity against HL60 cells.
In vitro cytotoxicity against HL60 cells.
|
[PMID: 11128648] |
| HL-60 | ED50 |
2.4 x 10-9 M
Compound: TTNPB (3)
|
The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte
The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte
|
[PMID: 2709376] |
| HL-60 | EC50 |
>1000 nM
Compound: 1
|
Transglutaminase activity in HL-60 cdm-1 cells
Transglutaminase activity in HL-60 cdm-1 cells
|
[PMID: 7636843] |
| HL-60 | EC50 |
>1000 nM
Compound: 9 (TTNPB)
|
Induction of transglutaminase (TGase) activity in HL-60 cells
Induction of transglutaminase (TGase) activity in HL-60 cells
|
[PMID: 8784454] |
TTNPB inhibits binding of [3H]tRA with IC50s of 3.8 nM, 4 nM, and 4.5 nM for human RARα, β, and γ, respectively. TTNPB competes for [3H]tRA binding to CRABPI with IC50s of 1800 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 71441-28-6
-
Appearance Solid
-
Molecular Weight 348.48
-
Formula C24H28O2
-
Color White to off-white
-
SMILES
O=C(O)C1=CC=C(/C=C(C2=CC=C3C(C)(C)CCC(C)(C)C3=C2)\C)C=C1
-
Synonyms
Ro 13-7410; Arotinoid acid; AGN191183
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity. [Abstract]2025 Nov 27:e09340. PMID: 41309490
TTNPB purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 27:e09340. [Abstract]
A) Flow cytometry analysis showing HLA-DR expression after IFN-γ +TTNPB (0.01 nM-100 μM) and IFN-γ +Bexarotene treatment for 48 h. B) Flow cytometry analysis showing CD40 expression after IFN +TTNPB and IFN-γ +Bexarotene treatment for 48 h in mast cells.
-
Biomaterials
Chemical induced conversion of mouse fibroblasts and human adipose-derived stem cells into skeletal muscle-like cells. [Abstract]2018 Dec 6;193:30-46. PMID: 30554025 -
Acta Pharmacol Sin
In situ reprogramming of cardiac fibroblasts into cardiomyocytes in mouse heart with chemicals. [Abstract]2024 Nov;45(11):2290-2299. PMID: 38890526
TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]
Schemes of generating Fsp1-Cre:R26R-loxp-tdTomato mice and drug treatment to induce in situ transdifferentiation. Fsp1-Cre mice were crossed with R26Rloxp-tdTomato mice in which the expression of tdTomato is prevented by a loxP-flanked STOP cassette. The F1 mice would have the red fluorescent protein tdTomato expressed specifically in the fibroblasts. CRFVPTM were given once a week for 6 weeks. Immunofluorescence staining of the cryosections of the hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with vehicle (b) or CRFVPTM (c) for 6 weeks. C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age.
TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]
Whole-heart imaging with light-sheet fluorescence microscopy after tissue clearing of the hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with vehicle (a) or CRFVPTM (b). (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).
TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]
a Schemes of obtaining PDGFRα-DreER:R26R-rox-tdTomato mice and drug treatment to induce in situ cardiac reprogramming in PDGFRα-DreER:R26R-roxtdTomato mice. PDGFRα-DreER mice were mated with R26R-rox-tdTomato mice in which the expression of tdTomato is prevented by a roxflanked STOP cassette. The expression of tdTomato in fibroblasts was turned on by tamoxifen treatment. CRFVPTM were given once a week for 6 weeks. b Body weigh change of the mice after chemical treatment. Immunofluorescence staining of the cryosections of the hearts from PDGFRα-DreER:R26R-rox-tdTomato mice treated with vehicle (c) or CRFVPTM (d) for 6 weeks. (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).
TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299. [Abstract]
Immunofluorescence staining of α-actinin in cryosections of hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with 7 C cocktail (CRFVPTM) or cocktails by removing 1 compound from 7 C (7C-X) for 6 weeks in vivo with Fsp1-Cre:R26R-loxp-tdTomato mice. (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).
-
Elife
Exploration of precision coregulator TR-FRET identifies diverse signatures for LXR ligands relevant to discovery of nonlipogenic ABCA1 inducers. [Abstract]2026 Jun 22:14:RP109146. PMID: 42325211 -
Biomedicines
Exosome-Mediated Differentiation of Mouse Embryonic Fibroblasts and Exocrine Cells into β-Like Cells and the Identification of Key miRNAs for Differentiation. [Abstract]2020 Nov 9;8(11):485. PMID: 33182285 -
Solvent & Solubility
DMSO : 8.33 mg/mL (23.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Labeled and unlabeled retinoids are added to nucleosol or cytosolic fractions in ethanol so that the total amount of ethanol added is constant in all tubes and did not exceed 2% of the incubation volume. The receptor preparations are incubated with retinoids at 47°C for 4-6 hr. Sephadex PD-10 desalting columns are used to separate bound radioligand from free radioligand after equilibrium is achieved. For competitive binding assays, varying concentrations of unlabeled competing ligand are incubated with the appropriate nucleosol or cytosol in the presence of a fixed concentration of [3H]tRA (sp act. 49.3 Ci/mmol) or [3H]9-cis RA (sp. act. 24.0 Ci/mmol). Final concentrations of [3H] tRA and [3H]9-cis RA for nuclear receptor binding assays are 5nM. Final concentrations of [3H]tRA for CRABP binding assays is 30 nM. The IC50s are calculated. For saturation kinetics, increasing concentrations of radiolabeled ligand ([3H]tRA sp. act. 49.3 Ci/mmol, [3H]TTNPB sp. act. 5.5 Ci/mmol) are added to the nucleosol of the appropriate receptor subtype in the presence (nonspecific binding) or absence (total binding) of a 100-fold molar excess of the corresponding unlabeled retinoid. Specific binding is defined as the total binding minus nonspecific binding. Saturation kinetics are calculated[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8696 mL | 14.3480 mL | 28.6961 mL | 71.7401 mL |
| 5 mM | 0.5739 mL | 2.8696 mL | 5.7392 mL | 14.3480 mL | |
| 10 mM | 0.2870 mL | 1.4348 mL | 2.8696 mL | 7.1740 mL | |
| 15 mM | 0.1913 mL | 0.9565 mL | 1.9131 mL | 4.7827 mL | |
| 20 mM | 0.1435 mL | 0.7174 mL | 1.4348 mL | 3.5870 mL |
Powered by Bioz